NASDAQ: BMEA - Biomea Fusion, Inc.

Yield per half year: +11.98%
Sector: Healthcare

Share chart Biomea Fusion, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Biomea Fusion, Inc., биофармацевтическая компания, занимается открытием, разработкой и коммерциализацией необратимых малых молекул для лечения пациентов с генетически определенными видами рака. Его ведущим продуктом-кандидатом является BMF-219, перорально биодоступный, мощный и селективный необратимый ингибитор MENIN, регулятора транскрипции в онкогенной передаче сигналов при множественных раковых заболеваниях. Компания была основана в 2017 году и имеет штаб-квартиру в Редвуд-Сити, штат Калифорния.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

P/BV 0.9942
EV/EBITDA 0.2
EBITDA -0.0012
Цена ао 12.15
Сайт https://biomeafusion.com
ISIN US09077A1060
Число акций ао 0.03587 млрд
Валюта usd
IPO date 2021-04-16
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: +5.93% (11.47)
Change price per week: +13.02% (10.75)
Change price per month: +47.09% (8.26)
Change price per 3 month: +135.47% (5.16)
Change price per half year: +11.98% (10.85)
Change price per year: +8.58% (11.19)
Change price per 3 year: +8% (11.25)
Change price per year to date: +21.14% (10.03)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.06 5
P/E 0 0
EV/EBITDA -2.87 0
Total: 3

Efficiency

Title Value Grade
ROA, % -58.65 0
ROE, % -69.28 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0844 10
Total: 9

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 10061.17 10
Yield EPS, % 3025.33 10
Total: 8
More

Institutions Volume Share, %
Aisling Capital Management LP 799 2.22
FMR, LLC 5 14.9
State Street Corporation 4 12.48
Cormorant Asset Management, LP 4 9.93
Laurion Capital Management, LP 3 7.57
Baker Brothers Advisors, LLC 2 5.87
Blackrock Inc. 2 5.49
Vanguard Group Inc 1 3.8
Janus Henderson Group PLC 1 3.58
Driehaus Capital Management, LLC 1 3.32

ETF Share, % Profitability for 1 year, % Dividends, %
ProShares Ultra Nasdaq Biotechnology 0.02071 51.697637072723 0.85651
Range Cancer Therapeutics ETF 0.70526 47.24446537918 0.11955
Dimensional US Core Equity Market ETF 0.00019 30.983243755928 1.40618
ProShares Hedge Replication ETF 0.00147 5.9237999659878 1.47892
Invesco Nasdaq Biotechnology ETF 0.03027 28.578975171685 0.8565
iShares Micro-Cap ETF 0.06056 34.327031588619 1.54048
iShares Russell 2000 Growth ETF 0.0179 38.042556988 0.6026
iShares Russell 3000 ETF 0.00031 31.230028873917 1.43482
Schwab U.S. Small-Cap ETF 0.00508 -34.641922436355 1.51433
Schwab U.S. Broad Market ETF 0.00036 -56.193181818182 1.43354
ProShares UltraPro Russell2000 0.00516 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.02 37.361289927043 0.60264
Vanguard Russell 2000 ETF 0.01 32.773459189339 1.48801
Principal Healthcare Innovators ETF 0.03021 618.4964157054 0.8416
Future Tech ETF 0.03021 426.33969118983 0.8416



Head Job title Payment Year of birth
Mr. Thomas Andrew Butler Co-Founder, Chairman & CEO 921.14k 1981 (43 years)
Mr. Ramses M. Erdtmann Co-Founder, President, COO & Director 659.53k 1963 (61 year)
Mr. Franco Valle CFO & Principal Accounting Officer 651.77k 1981 (43 years)
Mr. Heow Tan Chief Technology & Quality Officer N/A 1959 (65 years)
Ms. Naomi Cretcher Chief People Officer N/A
Dr. Thorsten Kirschberg Ph.D. Executive Vice President of Chemistry N/A 1970 (54 years)
Dr. Stephan Morris M.D. Chief Development Officer N/A
Mr. Ravi Upasani Executive Vice President of Intellectual Property N/A
Dr. Juan Pablo Frias M.D. Chief Medical Officer N/A
Caroline Perez- Dupont Senior Vice President of Contracts

Address: United States, Redwood City. CA, 900 Middlefield Road - open in Google maps, open in Yandex maps
Website: https://biomeafusion.com